冬病夏治联合胸腺法新治疗COPD稳定期D组疗效观察  

Efficacy of winter diseases treated in summer plus thymalfasin on stable phase of COPD in D group

作　　者：费湘平[1] 陈立音 

机构地区：[1]丹阳市人民医院,江苏丹阳212300

出　　处：《中医临床研究》2017年第23期7-9,共3页Clinical Journal Of Chinese Medicine

摘　　要：目的:观察冬病夏治法联合胸腺法新治疗慢性阻塞性肺疾病(COPD)稳定期D组患者的临床疗效。方法:将80例COPD稳定期D组患者随机分为观察组和对照组,各40例,两组均给予吸入布地奈德福莫特罗粉吸入剂的常规药物治疗,观察组加用冬病夏治消喘膏外敷联合皮下注射胸腺法新。治疗结束后,观察两组治疗有效率、细胞免疫指标(CD4^+、CD4^+/CD8^+)、肺功能指标(FEV_1/FVC、FEV_1%)、慢阻肺患者自我评估测试问卷评分(CAT评分),治疗结束后3个月随访急性加重次数。结果:治疗结束后,两组间疗效比较,观察组的总有效率、细胞免疫指标、肺功能指标、CAT评分、急性加重次数均优于对照组,差异有统计学意义(P<0.05);同组治疗前后比较,两组肺功能指标、CAT评分较前均有好转(P<0.05),但在细胞免疫指标方面,观察组较前改善明显(P<0.05),而对照组则无明显变化(P>0.05)。结论:临床中使用冬病夏治法联合胸腺法新能缓解COPD稳定期D组患者临床症状,并且可以增强机体免疫力,改善肺功能状况,提高生活质量,减少急性加重的次数。Objective:To observe the effect of winter disease treated in summer plus thymalfasin on stable phase of COPD in D group.Methods:80patients were randomly divided into the observation group(n=40)and control group(n=40).The groups were given conventional treatment of inhaled symbicort turbuhaler;and the observation group added winter disease treated in summer with XiaochuanGao plus subcutaneous injection of thymalfasin.After the treatment,the clinical efficacy,cellular immune index(CD4+,CD4+/CD8+),pulmonary function index(FEV1/FVC,FEV1%),COPD patients CAT score were observed in two groups.And the number of acute exacerbations was followed up within3months after treatment.Results:After the treatment,the total efficiency,cellular immunity index,pulmonary function index,CAT score,the numbers of acute exacerbations in the observation group were better than those in the control group;and the difference was statistically significant(P<0.05).the pulmonary function index and CAT score in groups were all improved(P<0.05).However,the cellular immunity index in the observation group was more improved than before(P<0.05).while the control group had no significant change(P>0.05).Conclusion:Winter disease treated in summer plus thymalfasin can relieve the clinical symptoms of patients with stable phase of COPD in D group,enhance immunity,improve pulmonary function and quality of life,and reduce the number of acute exacerbations.

关 键 词：慢性阻塞性肺疾病 稳定期 冬病夏治 胸腺法新 肺功能 

分 类 号：R563[医药卫生—呼吸系统]